Margetuximab
Sign in to saveAlso known as MGAH22
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2020
- Admin. routes
- parenteral
- Indications
- breast cancer, neoplasm
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
Show 3 more facts
- World Health Organisation international non-proprietary name
- margetuximab
- subject has role
- monoclonal antibody
- physically interacts with
- Erb-b2 receptor tyrosine kinase 2
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
3 sectionsContents
- Medical uses
- History
- References
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.
The most common adverse drug reactions in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodysesthesia, and extremity pain.
Excerpted from Wikipedia’s “Margetuximab” article, available under the CC BY-SA 4.0 licence.